|
1
|
Ferlay J, Autier P, Boniol M, Heanue M,
Colombet M and Boyle P: Estimates of the cancer incidence and
mortality in Europe in 2006. Ann Oncol. 18:581–592. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Petrovich Z, Lieskovsky G, Stein JP,
Huberman M and Skinner DG: Comparison of surgery alone with surgery
and adjuvant radiotherapy for pT3N0 prostate cancer. BJU Int.
89:604–611. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Spahn M, Joniau S, Gontero P, Fieuws S,
Marchioro G, Tombal B, Kneitz B, Hsu CY, Van Der Eeckt K, Bader P,
et al: Outcome predictors of radical prostatectomy in patients with
prostate-specific antigen greater than 20 ng/ml: A European
multi-institutional study of 712 patients. Eur Urol. 58:1–7. 10–11.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wilt TJ, Brawer MK, Jones KM, Barry MJ,
Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, et al:
Prostate Cancer Intervention versus Observation Trial (PIVOT) Study
Group: Radical prostatectomy versus observation for localized
prostate cancer. N Engl J Med. 367:203–213. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Roodman GD: Mechanisms of bone metastasis.
N Engl J Med. 350:1655–1664. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mundy GR: Metastasis to bone: Causes,
consequences and therapeutic opportunities. Nat Rev Cancer.
2:584–593. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ye L, Kynaston HG and Jiang WG: Bone
metastasis in prostate cancer: Molecular and cellular mechanisms
(Review). Int J Mol Med. 20:103–111. 2007.PubMed/NCBI
|
|
8
|
Catto JW, Miah S, Owen HC, Bryant H, Myers
K, Dudziec E, Larré S, Milo M, Rehman I, Rosario DJ, et al:
Distinct microRNA alterations characterize high- and low-grade
bladder cancer. Cancer Res. 69:8472–8481. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Croce CM: Causes and consequences of
microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pang Y, Young CY and Yuan H: MicroRNAs and
prostate cancer. Acta Biochim Biophys Sin (Shanghai). 42:363–369.
2010. View Article : Google Scholar
|
|
13
|
Wang G, Wang Y, Feng W, Wang X, Yang JY,
Zhao Y, Wang Y and Liu Y: Transcription factor and microRNA
regulation in androgen-dependent and -independent prostate cancer
cells. BMC Genomics. 9(Suppl 2): S222008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Si ML, Zhu S, Wu H, Lu Z, Wu F and Mo YY:
miR-21-mediated tumor growth. Oncogene. 26:2799–2803. 2007.
View Article : Google Scholar
|
|
15
|
Lin SL, Chiang A, Chang D and Ying SY:
Loss of mir-146a function in hormone-refractory prostate cancer.
RNA. 14:417–424. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Peng X, Guo W, Liu T, Wang X, Tu X, Xiong
D, Chen S, Lai Y, Du H, Chen G, et al: Identification of miRs-143
and -145 that is associated with bone metastasis of prostate cancer
and involved in the regulation of EMT. PLoS One. 6:e203412011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tavazoie SF, Alarcón C, Oskarsson T, Padua
D, Wang Q, Bos PD, Gerald WL and Massagué J: Endogenous human
microRNAs that suppress breast cancer metastasis. Nature.
451:147–152. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu Y, Zhao F, Wang Z, Song Y, Luo Y, Zhang
X, Jiang L, Sun Z, Miao Z and Xu H: MicroRNA-335 acts as a
metastasis suppressor in gastric cancer by targeting Bcl-w and
specificity protein 1. Oncogene. 31:1398–1407. 2012. View Article : Google Scholar :
|
|
19
|
Wang YX, Zhang XY, Zhang BF, Yang CQ, Chen
XM and Gao HJ: Initial study of microRNA expression profiles of
colonic cancer without lymph node metastasis. J Dig Dis. 11:50–54.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Marcucci G, Maharry K, Radmacher MD,
Mrózek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus
CD, Liu CG, et al: Prognostic significance of, and gene and
microRNA expression signatures associated with, CEBPA mutations in
cytogenetically normal acute myeloid leukemia with high-risk
molecular features: A Cancer and Leukemia Group B Study. J Clin
Oncol. 26:5078–5087. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Soon PS, Tacon LJ, Gill AJ, Bambach CP,
Sywak MS, Campbell PR, Yeh MW, Wong SG, Clifton-Bligh RJ, Robinson
BG, et al: miR-195 and miR-483-5p identified as predictors of poor
prognosis in adrenocortical cancer. Clin Cancer Res. 15:7684–7692.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sorrentino A, Liu CG, Addario A, Peschle
C, Scambia G and Ferlini C: Role of microRNAs in drug-resistant
ovarian cancer cells. Gynecol Oncol. 111:478–486. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lynch J, Fay J, Meehan M, Bryan K, Watters
KM, Murphy DM and Stallings RL: MiRNA-335 suppresses neuroblastoma
cell invasiveness by direct targeting of multiple genes from the
non-canonical TGF-β signalling pathway. Carcinogenesis. 33:976–985.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ronchetti D, Lionetti M, Mosca L, Agnelli
L, Andronache A, Fabris S, Deliliers GL and Neri A: An integrative
genomic approach reveals coordinated expression of intronic
miR-335, miR-342, and miR-561 with deregulated host genes in
multiple myeloma. BMC Med Genomics. 1(37)2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang H, Luo XQ, Zhang P, Huang LB, Zheng
YS, Wu J, Zhou H, Qu LH, Xu L and Chen YQ: MicroRNA patterns
associated with clinical prognostic parameters and CNS relapse
prediction in pediatric acute leukemia. PLoS One. 4:e78262009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bing L, Hong C, Li-Xin S and Wei G:
MicroRNA-543 suppresses endometrial cancer oncogenicity via
targeting FAK and TWIST1 expression. Arch Gynecol Obstet.
290:533–541. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ying L and Hofseth LJ: An emerging role
for endothelial nitric oxide synthase in chronic inflammation and
cancer. Cancer Res. 67:1407–1410. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lala PK and Chakraborty C: Role of nitric
oxide in carcinogenesis and tumour progression. Lancet Oncol.
2:149–156. 2001. View Article : Google Scholar
|
|
29
|
Dhar A, Brindley JM, Stark C, Citro ML,
Keefer LK and Colburn NH: Nitric oxide does not mediate but
inhibits transformation and tumor phenotype. Mol Cancer Ther.
2:1285–1293. 2003.
|
|
30
|
Simeone AM, Colella S, Krahe R, Johnson
MM, Mora E and Tari AM: N-(4-Hydroxyphenyl)retinamide and nitric
oxide pro-drugs exhibit apoptotic and anti-invasive effects against
bone metastatic breast cancer cells. Carcinogenesis. 27:568–577.
2006. View Article : Google Scholar
|
|
31
|
Fabbri F, Brigliadori G, Ulivi P, Tesei A,
Vannini I, Rosetti M, Bravaccini S, Amadori D, Bolla M and Zoli W:
Pro-apoptotic effect of a nitric oxide-donating NSAID, NCX 4040, on
bladder carcinoma cells. Apoptosis. 10:1095–1103. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jadeski LC, Chakraborty C and Lala PK:
Role of nitric oxide in tumour progression with special reference
to a murine breast cancer model. Can J Physiol Pharmacol.
80:125–135. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Qian J, Jenkins RB and Bostwick DG:
Genetic and chromosomal alterations in prostatic intraepithelial
neoplasia and carcinoma detected by fluorescence in situ
hybridization. Eur Urol. 35:479–483. 1999. View Article : Google Scholar : PubMed/NCBI
|
